FGF9 and metabolic dysfunction-associated steatohepatitis: To further explore the contribution of FGF9 to NASH‐driven HCC, liver‐specific FGF9 transgenic (FGF9Alb) mice were generated by crossing FGF9 Rose26 mice (FGF9Rosa26) with mice with albumin promoter‐induced Cre expression (Alb‐Cre mice), which resulted in a 6‐fold increase in liver FGF9 expression (both mRNA and protein) compared with that in control mice (FGF9Rosa26 mice) (Figure S6, Supporting Information).